EGFR基因突变阳性肺癌延缓耐药与克服耐药——中山大学肿瘤防治中心肺癌内科团队的研究探索  

SYSUCC Study on Delaying and Overcoming Drug Resistance in EGFR Gene Mutation-Positive Lung Cancer

作　　者：周华强 占建华 方文峰 张力[1] ZHOU Huaqiang;ZHAN Jianhua;FANG Wenfeng;ZHANG Li(State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国细胞生物学学报》2025年第3期686-691,共6页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:82173101、82373262、82241232、82272789);中山大学肿瘤防治中心青年人才提升计划(批准号:YTP-SYSUCC-0096)资助的课题。

摘　　要：肺癌是我国及世界发病率和死亡率最高的恶性肿瘤,约30%的晚期肺癌患者属于表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变型。目前国内外肺癌治疗指南都推荐将表皮生长因子受体–酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitors,EGFR-TKIs)用于EGFR基因突变型的晚期肺癌患者的一线治疗,但大部分患者EGFR-TKIs治疗后可出现耐药,导致疾病进展。中山大学肿瘤防治中心肺癌内科团队在EGFR突变阳性肺癌领域进行了系统性创新研究,从延缓耐药到克服耐药,从联合化疗到双特异性抗体和抗体偶联药物等创新药物,为患者提供了多元化、精准化的治疗策略。该文将对中肿肺癌内科在EGFR基因突变阳性肺癌延缓耐药与克服耐药领域的研究成果进行综述。Lung cancer is the most common malignant tumor with the highest incidence and mortality rates in China and worldwide.About 30%of advanced lung cancer patients have EGFR(epidermal growth factor receptor)gene mutations.Currently,both domestic and international lung cancer treatment guidelines recommend using EGFR-TKIs(EGFR-tyrosine kinase inhibitors)as first-line treatment for advanced lung cancer patients with EGFR gene mutations.However,most patients develop resistance to TKI treatment,leading to disease progression.The internal medicine team at the Sun Yat-sen University Cancer Center has conducted innovative research in the field of EGFR mutation-positive lung cancer,ranging from delaying drug resistance to overcoming drug resistance,from combination chemotherapy to novel drugs such as bispecific antibodies and antibody drug conjugates,providing patients with diversified and precise treatment strategies.This article will review the research results of the SYSUCC lung cancer team in the field of delaying drug resistance and overcoming drug resistance in EGFR gene mutationpositive lung cancer.

关 键 词：肺癌 EGFR 耐药 双特异性抗体 抗体偶联药物 

分 类 号：R73[医药卫生—肿瘤]